Peptide Decoding
New?New to peptides?Start here →
Decoding

PDA (Pentadeca Arginate)_Dosage, benefits & legal status

Also known as pentadeca arginate, BPC-157 arginate, PDA

Published July 22, 2026 · Updated August 14, 2026

A newer, more stable cousin of BPC-157 for faster healing.

Healing & recoveryBPC-157 relativeResearch only
Common vial size10 mg
Dose0.25 up to 0.5 mg per day (start low, increase slowly)
Frequency1-2x daily
RouteUnder the skin (subcutaneous)
StatusResearch only
CycledCommonly run in 4 to 8 week blocks, like BPC-157

Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.

01

What is PDA (Pentadeca Arginate)?

Plain language first. The technical label stays, but it never stands alone.

Overview

It aims to do the same repair job, healing gut, tendon, and muscle, while lasting longer in the body. It is very new.

The technical version

PDA (pentadeca arginate) is a more stable, arginate-salt cousin of BPC-157.

What it's used for

A newer, more stable cousin of BPC-157, used for the same thing: faster healing of gut, tendons, muscle, and inflammation. It is marketed as longer-lasting.

02

How does PDA (Pentadeca Arginate) work?

What it does in the body, and where.

PDA is BPC-157 as an arginate salt rather than an acetate salt. The peptide chain is the same; the counter-ion is different.

  1. 01
    The repair mechanism is BPC-157's
    Blood vessel growth and repair signalling, with the same animal evidence behind it.
  2. 02
    The arginate form is claimed to be more stable
    Better shelf life and survival in the body. This is a formulation claim from vendors, not something established in published work.
  3. 03
    It is very new and essentially unstudied
    Even by the standards of this category, there is almost nothing published on PDA specifically as distinct from BPC-157.
Where it acts
GutTendonMuscle

Where this compound is thought to act.

03

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

  • Healing gut, tendon, and muscle, marketed as a longer-lasting version of BPC-157Research only
  • Joint and connective tissue recoveryResearch only

The published record

Research index

0

Records indexed for PDA (Pentadeca Arginate)

Europe PMC was searched on 12 September 2026 and returned nothing.

Counted from Europe PMC indexing, not read by a person.

PDA (Pentadeca Arginate) vial rendering
Compound field notes

At a glance

Four things to know about PDA (Pentadeca Arginate)

01

Evidence

Research only

02

Category

Healing and recovery

03

Common vial

10 mg

04

Half-life

Nothing published

04

How much, and do you cycle it?

The range, and whether you take breaks.

0.25 up to 0.5 mg per day (start low, increase slowly), 1-2x daily. Commonly run in 4 to 8 week blocks, like BPC-157Community practice

Same convention as BPC-157, which it is a salt form of. No human study has tested a duration.

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

Nothing publishedNo figure

Nothing published for pentadeca arginate. BPC-157, the sequence it is built on, has no published human figure either.

You can compare this against the whole library to see where it sits.

06

How do I dose and price it?

Enter your vial and your dose. Pick a mix. We show the draw and the cost.

The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.

Your vial size (mg)
Printed on the vial.
What you paid per vial
$
Used for cost per dose only.
Your dose (mcg)
Commonly referenced range: 0.25 up to 0.5 mg per day (start low, increase slowly)Community practice

Choose your mix

your own mL
units · —
Enter your own volume

Measuring the water1 mL = one full 100-unit syringe.

Your draw

5 / 100 units
What it costs

PDA (Pentadeca Arginate) starts at $44.00 across 3 vendors, typically $4.40 per mg.

4 listings, last read Sep 4, 2026. Shipping and card fees are not included.

See all 4 listings →
07

How do you store it?

Before mixing, and after.

Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.

Unmixed lyophilized PDA (Pentadeca Arginate) keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.

Who should avoid it

Check these before anything else.
  • No published human trials exist, so no contraindications are established
  • Pregnancy
  • Active cancer, as a precaution given the healing mechanism

Stop and get help

These are emergencies. Seek care.
  • Signs of an allergic reaction
  • Anything unusual, given the absence of human data

Common effects

Expected, and usually mild.
  • Unknown in humans. Despite heavy marketing, there is no published human trial data

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

09

Is PDA (Pentadeca Arginate) approved?

And where the numbers on this page come from.

No. PDA (Pentadeca Arginate) is not approved for any use, anywhere. It is sold labelled for laboratory research only, and there is no legal route to buy it for human use.

  • Approval status
    Research only
  • Route
    Under the skin (subcutaneous)
  • Checked
    July 2026

What has happened recently

We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.

You can compare this against the whole library, or read how to check a seller.


Guides for this compound

Sources

  • FDA, bulk drug substances nominated for use in compounding under section 503A, updated 14 May 2026(2026)
    This compound appears in none of the three categories on FDA's nomination list, including category 3, which is the catch-all for substances someone proposed without supplying enough information to evaluate them. This list is the comprehensive record of what has been proposed for pharmacy compounding since the process opened in 2013, when over two thousand substances were nominated, so absence from all three categories means no one has ever put this compound forward.

Last reviewed 22 July 2026